

Diary No: 32003  
Date: 07.12.17

**F. No 12-47/14-DC (Pt-D)**

Tele No.011-23236965  
Fax.No.011-23236973

**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organization**  
**FDA Bhawan, New Delhi - 110002 (India)**  
**New Drugs Division**

Dated: 18-01-2018

To  
M/s. MSN Laboratories Private Ltd.,  
MSN House, Plot No: C-24,  
Industrial Estate, Sanathnagar,  
Hyderabad-500 018

**Subject:** Permission for conducting a clinical study entitled, "A double blind, Double dummy, Randomized, Multicentric, Active controlled, Parallel group, Prospective, Comparative Phase III study to evaluate the Efficacy and Safety of Anagliptin versus Sitagliptin added to ongoing Metformin Therapy in Patients with Type 2 DM Insufficiently Controlled with Metformin alone".

**CT NOC No.** CT/ND/03/2018

**Reference:** Your application no. 52/ Anagliptin /Oct/2016-17, dated- 04-12-2017 on the subject mentioned above.

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the following investigators and as per the **Protocol No: OLS/MSN/ANAGLIPTIN/CT-III/16, Version No: 01, Dated 29.08.2016** submitted to this Directorate.

S.No	Investigator & Trial site	Ethics Committee Name/Registration Number
1.	Dr.B.L.N.Prasad, MBBS. MD Rajiv Gandhi Institute of Medical Sciences and RIMSGGH, Srikakulam -532 001, AP, India	Institutional Ethics Committee, Rajiv Gandhi Institute of Medical Sciences and RIMSGGH. Srikakulam, -532001, AP, India. <b>ECR/492/Inst/AP/2013</b>
2.	Dr. K. Praveen, MBBS, D.N.B Kakatiya Hospital #12-52, Road No:2, P & T colony, Near Uppal Depot, Medipally, Hyderabad-500039	Kakatiya Hospital Ethics Committee, #12-52, Road No:2, P & T colony, Near Uppal Depot, Medipally, Hyderabad -500039 <b>ECR/652/Inst/TG/2014</b>
3.	Dr. Dibakar Biswas, Assistant Professor, MBBS, MD IPGME&R/SSKM Hospital, Department of Endocrinology. 244 J.C Bose Road, Kolkata - 700020. West Bengal. India	IPGME&R Research Oversight Committee (Institutional Ethics Committee for Research Involving Human Subjects)IPGME & R/SSKM Hospital, 244 J.C Bose Road, Kolkata -700020, West Bengal <b>ECR/35/Inst/WB/2013</b>

4.	Dr.Pravin Uttamrao Shingade MD Government Medical College and Hospital, Medical College square, Nagpur- 440003, Maharashtra, India	Institutional Ethics Committee Government Medical College and Hospital, Nagpur-440 003. Maharashtra, India. <b>ECR/43/Inst/MH/2013</b>
5.	Dr.Deepak Khandelwal MBBS, MD, DM. Maharaja Agrasen Hospital, West Punjabi Bagh, New Delhi-110 026	Institution Ethics Committee Maharaja Agrasen Hospital, R.No, 614, 6 <sup>th</sup> Floor West Punjabi Bagh, New Delhi-110026. <b>ECR/745/Inst/DL/2015</b>

**Kindly note that the clinical trial permission is subject to the Following conditions:**

- a) Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.
- b) Approval of Institutional Ethics Committee duly registered with CDSCO (under Rule 122DD of Drugs & Cosmetics Rules) should be obtained and submitted to this Directorate before initiation of the study.
- c) Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.
- d) Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.
- e) Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.
- f) In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.
- g) The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.

- h) The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.
- i) Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.
- j) The sponsor shall ensure that the number of clinical trials an investigator can undertake should be commensurate with the nature of the trial, facility available with the Investigator etc. However, under no circumstances the number of trials to be conducted by an Investigator should be more than three at a time.
- k) The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.
- l) In addition to the requirement of obtaining written informed consent, an audio-video recording of the informed consent process in case of vulnerable subjects in clinical trial of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record; provided that in case of clinical trial of anti-HIV and anti-leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record, as per Government of India, Gazette Notification vide G. S. R. no. 611(E) dated 31.07.2015.
- m) The formulation intended to be used in the clinical trial shall be manufactured under GMP conditions using validated procedures and shall have ongoing stability programme.
- n) If the clinical trial batches are different from that of the primary batches for which data have been submitted, stability reports for clinical trial batches are to be submitted as per Appendix IX of schedule Y of drugs and Cosmetics Rules for Drug substances and formulation along with Clinical study Report.

- o) It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.
- p) Informed consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect as per the requirements specified in Appendix V of Schedule Y of the Drugs and Cosmetics rules, 1945 must be got approved from the respective Ethics Committee and submitted to CDSCO before enrolling first subject at the respective sites
- q) Bioequivalence with the reference product shall be established before initiation of the clinical trial.

**Yours faithfully,**



**(Dr. G.N.Singh)**  
**Drugs Controller General (India)**